EUVIMEDEUVIMED entdecken
Open Access

The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment

Asumi Iesato, Stephanie Li, Peter M Sadow iD, Mohammadreza Abbasian, Ara Nazarian, Jack Lawler, Carmelo Nucera

Thyroid® · 2023

DOI: 10.1089/thy.2022.0597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2023. Verfasst von Asumi Iesato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Human Thyroid Cancers Preclinical and Translational Research Program, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Cen…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansAnimalsMicePericytesThrombospondin 1Tyrosine Kinase InhibitorsTumor MicroenvironmentProto-Oncogene Proteins B-rafIodine RadioisotopesProtein Kinase InhibitorsDisease Models, AnimalPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

BRAFV600EPDGFR-βanaplastic thyroid cancerlenvatinibpericyte

Substanzen

Thrombospondin 1Tyrosine Kinase InhibitorsProto-Oncogene Proteins B-rafIodine RadioisotopesProtein Kinase InhibitorslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Human Thyroid Cancers Preclinical and Translational Research Program, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Ha…
  • Center for Vascular Biology Research (CVBR), Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Musculoskeletal Translational Innovation Initiative, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

ORCID-Profile: Peter M Sadow

Förderung

  • NCI NIH HHS

Zitieren

APA

Iesato, A., Li, S., Sadow, P. M., Abbasian, M., Nazarian, A., Lawler, J., & Nucera, C. (2023). The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Thyroid®. https://doi.org/10.1089/thy.2022.0597

Vancouver

Iesato A, Li S, Sadow PM, Abbasian M, Nazarian A, Lawler J, et al. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Thyroid®. 2023. doi:10.1089/thy.2022.0597

BibTeX
@article{Iesato2023,
  author = {Iesato, Asumi and Li, Stephanie and Sadow, Peter M and Abbasian, Mohammadreza and Nazarian, Ara and Lawler, Jack and Nucera, Carmelo},
  title = {The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment},
  journal = {Thyroid®},
  year = {2023},
  doi = {10.1089/thy.2022.0597}
}
Kostenlos starten →